We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Calliditas Therapeutics AB | NASDAQ:CALT | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.4532 | -2.01% | 22.1368 | 22.20 | 22.40 | 22.36 | 22.0175 | 22.32 | 1,406 | 18:35:19 |
From Feb 2024 to May 2024
STOCKHOLM, March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.
Carnegie Healthcare Seminar, Wednesday, March 6, 2024. Fireside chat will be held at 10:20 - 10:50 am CET and one-on-one meetings will be available.
Jefferies Biotech on the Bay Summit, Wednesday, March 13, 2024 in Miami, FL, one-on-one meetings will be available.
Leerink Partners Global Biopharma Conference on March 12, 2024 in Miami, FL.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact person set out above, on March 1, 2024, at 13:00 CET.
The following files are available for download:
https://mb.cision.com/Main/16574/3939155/2640916.pdf | PM_March Events_ENG |
View original content:https://www.prnewswire.co.uk/news-releases/calliditas-therapeutics-to-attend-investor-conferences-in-march-302077153.html
Copyright 2024 PR Newswire
1 Year Calliditas Therapeutics AB Chart |
1 Month Calliditas Therapeutics AB Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
